Abstract: ObjectiveTo study and evaluate the application value of HE4, CA125 and PDGF-BB detections for diagnosis and clinical staging of ovarian malignant tumors . Methods216 patients were divided into two groups. Group one (premenopausal group) included 26 cases of malignant ovary tumor and 53 cases of benign ovary tumor, and 60 cases of healthy women as control. Group two (emenopausal group) comprised of 50 cases of malignant ovary tumor, 87 cases of benign ovary tumor and 108 cases of healthy women. HE4, CA125 and PDGF-BB in sera of patients were detected with ICMA and ELISA and the clinical application value in diagnosis of malignant ovarian tumor was analyzed. ResultsThe levels of HE4, CA125 and PDGF-BB in the cases of malignant ovary tumor were significantly higher than those of benign tumors and healthy women (P <0.01). Spearman correlation analysis was staticstically significantly and HE4 was the highest correlation (r=0.613). The sensitivity of HE4 and CA125 was higher than that of PDGF-BB (P <0.05) while no difference was observed between HE4 and CA125 (P>0.05). At the same time, the specificity and accuracy of HE4 reached 88.1% and 87.1%, respectively when the level of 36.5pmol/L was taken as the threshold value in premenopausal group. In the menopausal group, however, the specificity and accuracy were found to be 93.5% and 88.7% respectively if the cut-off value of 56.8pmol/L was used. ConclusionMornitoring of the three seral tumor markers of serum HE4, CA125 and PDGF-BB possesses a practical significance in helping to master the situation of patients, efficacy of treatments, and assessment of prognosis of malignant ovarian tumors.

Key words: Ovarian, neoplasm, Tumor, marker, Human, epididymis, protein, 4, Vascular, endothelial, growth, factor